Valneva Stock Continues its Rebound, Closing at 4.39 Euros

Valneva's stock gained 2.81% this Friday, January 16, closing at 4.39 euros after opening at 4.27 euros. The French vaccine specialist thus confirms a positive momentum with a weekly advance of 5.13% and a spectacular yearly rise of 108.4%. This performance is part of a favorable technical environment, with the stock price now moving above its key moving averages. The Relative Strength Index has reached 74, indicating a potential overbought zone that reflects the recent strength of the bullish movement. Meanwhile, the stock price is approaching a major resistance at 4.43 euros, a symbolic threshold whose crossing could pave the way for a new impulse. With a trading volume representing 0.42% of the capital, the stock shows moderate activity that underscores a gradual progression rather than speculative frenzy.

The recent evolution of the stock occurs in a context marked by several strategic developments. In early January, Valneva terminated its licensing agreement with the Serum Institute of India and regained full commercialization rights for IXCHIQ, its chikungunya vaccine, for endemic countries. This decision aims to optimize supply chain control and accelerate access in areas most affected by the disease. In December, the laboratory also announced positive results for its Phase 2 study on the pediatric population. Regarding recommendations, Stifel reiterated its buy rating on January 6 with a raised target price of 10 euros, representing a potential upside of 128% from the current price, reflecting market hopes for the company's pipeline, including the Lyme disease vaccine candidate developed with Pfizer.